CVE-2022-28877

Local Privilege Escalation Vulnerability in F-Secure & WithSecure Windows Endpoint Products

Description

This vulnerability allows local user to delete arbitrary file in the system and bypassing security protection which can be abused for local privilege escalation on affected F-Secure & WithSecure windows endpoint products. An attacker must have code execution rights on the victim machine prior to successful exploitation.

Remediation

Solution:

  • FIX No User action is required. The required fix has been published through automatic update channel with UlcoreWin database on 2022-07-19_01
4.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.03%
Vendor Advisory f-secure.com Vendor Advisory withsecure.com
Affected: F-Secure and WithSecure All F-Secure and WithSecure Endpoint Protection Products for Windows
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2022-28877?
CVE-2022-28877 has been scored as a medium severity vulnerability.
How to fix CVE-2022-28877?
To fix CVE-2022-28877: FIX No User action is required. The required fix has been published through automatic update channel with UlcoreWin database on 2022-07-19_01
Is CVE-2022-28877 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2022-28877 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-28877?
CVE-2022-28877 affects F-Secure and WithSecure All F-Secure and WithSecure Endpoint Protection Products for Windows.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.